Dermatomyositis is a chronic autoimmune inflammatory disease with limited targeted treatment options. Brepocitinib, a first-in-class, oral, selective TYK2–JAK1 inhibitor, blocks cytokine signaling implicated in disease pathogenesis. To evaluate its therapeutic potential, a clinical study assessed the safety and efficacy of brepocitinib in 241 patients with dermatomyositis. The study found that brepocitinib 30 mg significantly improved disease activity in patients with dermatomyositis compared with placebo.
At week 52, the mean Total Improvement Score was 46.5 in the brepocitinib 30-mg group, 37.5 in the brepocitinib 15-mg group, and 31.2 in the placebo group. The treatment difference versus placebo was 15.3 points with brepocitinib 30 mg and 6.3 points with brepocitinib 15 mg. Brepocitinib 30 mg was superior across all nine key secondary endpoints, with improvements evident by week 4.…
